Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization

View Full Paper
Ask AI
Bookmark
Share

Authors

YVYannis K. ValtisDNDavid NemirovskyKCKuo‐Kai Chin

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals outpatient blinatumomab reduces hospitalization and toxicity rates in B-ALL patients, indicating effective treatment approach.

Key Points

  • To assess the safety of outpatient administration of blinatumomab and its impact on toxicity and healthcare utilization in B-ALL patients.
  • Retrospective cohort study of adult B-ALL patients treated with blinatumomab from 2012 to 2024 at two centers.
  • Assessment of toxicity outcomes (CRS and NTX) graded per ASTCT criteria.
  • Comparison of healthcare utilization including hospitalization days between outpatient and inpatient administration.
  • Outpatient blinatumomab during C1 had no Gr3+ CRS/NTX and lower hospitalization compared to inpatient treatment.
  • C2 outpatient initiation led to significantly lower median hospitalization days (3 vs. 14).
  • No increased rates of CRS or NTX were observed with outpatient administration in both cycles.

Cite This Study

Valtis et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236dda7https://doi.org/10.1182/blood-2025-1078
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens2025 · 1 citations
  2. 2Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab2025 · 1 citations
  3. 3Use and outcomes following blinatumomab rechallenge in adolescents and young adults (AYA) and adults with B-cell acute lymphoblastic leukemia (B-ALL)2025
  4. 4The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study2025 · 2 citations
  5. 5Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis2025 · 2 citations